MEDIA RELEASE PR35383
Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to
Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))
SAN DIEGO, July 14 /PRNewswire-AsiaNet/ --
With the recent FDA approval of the new P2Y12 inhibitor, prasugrel
(Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not
only able to assess response to Plavix(R), but also its newly approved
competitor, Effient. In obtaining a result from the VerifyNow System,
physicians are provided objective information to determine the response of an
individual patient to their antiplatelet therapy, regardless of the P2Y12
inhibitor that is prescribed.
"We are very excited with our product position and timing with the release
of this therapeutic alternative to Plavix," said Timothy I. Still, President
and CEO of Accumetrics. "We feel the VerifyNow System can dramatically
contribute to a physician's ability to enhance care for patients undergoing
percutaneous coronary intervention and receiving the antiplatelet therapy that
follows. In having this alternative therapy, physicians can now utilize the
results of the VerifyNow System to assist in the selection of the therapy that
best achieves the desired antiplatelet effect."
Accumetrics' VerifyNow P2Y12 Test is used to measure the level of P2Y12
receptor blockade and has been in used globally to assess a patient's response
to both clopidogrel and prasugrel in clinical trials as well as in clinical
practice within the hospital and physician office settings.
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic tests
for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy to use platform
for measuring an individual's response to multiple antiplatelet agents.
Addressing every major antiplatelet drug, including FDA-cleared products for
aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)),
and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the
VerifyNow System provides a valuable tool to help physicians make informed
treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin
is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered
trademark of Sanofi-Aventis. Effient is a registered trademark of Lilly-Daiichi
Sankyo.
CONTACT:
Jules Abraham
Lippert/Heilshorn & Associates
212-838-3777
jabraham@lhai.com
Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com
SOURCE: Accumetrics
CONTACT: Jules Abraham of Lippert/Heilshorn & Associates, +1-212-838-3777,
jabraham@lhai.com for Accumetrics; or Timothy I. Still, President and CEO of
Accumetrics, +1-858-404-8260, press@accumetrics.com
Translations:
NEWS 
